StockData
Autolus Therapeutics plc logo

Autolus Therapeutics plc (AUTL) stock

AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3020% below fair value
$1.09−0.05 (-4.39%)

Close on Nov 17, 2026Market cap $290.12MP/E –Yield –

Autolus Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Autolus Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -238.7%. For fiscal 2025 it was -381.4%, against -2180.5% the year before. The highest annual figure on record is -381.4% in fiscal 2025.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-381.4%+1799.1
FY2024Dec 31, 2024-2180.5%+10091.8
FY2023Dec 31, 2023-12272.3%−9091.7
FY2018Sep 30, 2018-3180.6%−2015.4
FY2017Sep 30, 2017-1165.2%−129.7
FY2016Sep 30, 2016-1035.5%–

Quarterly profit margin

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange (pts)
Q2 FY2026CQ2 2026Jun 30, 2026-85.6%+143.4
Q1 FY2026CQ1 2026Mar 31, 2026-273.1%+508.0
Q4 FY2025CQ4 2025Dec 31, 2025-371.9%+94821.2
Q3 FY2025CQ3 2025Sep 30, 2025-373.3%+148.8
Q2 FY2025CQ2 2025Jun 30, 2025-229.0%+12137.5
Q1 FY2025CQ1 2025Mar 31, 2025-781.1%+10155.7
Q4 FY2024CQ4 2024Dec 31, 2024-95193.1%−86354.9
Q1 FY2024CQ1 2024Mar 31, 2024-522.1%+3666.8
Q1 FY2021CQ1 2021Mar 31, 2021-12366.5%−10639.7
Q2 FY2020CQ2 2020Jun 30, 2020-10936.9%−7679.7
Q1 FY2020CQ1 2020Mar 31, 2020-8838.2%–
Q4 FY2018CQ3 2018Sep 30, 2018-4188.9%–
Q3 FY2018CQ2 2018Jun 30, 2018-1726.9%–
Q1 FY2018CQ4 2017Dec 31, 2017-3257.1%–

More Autolus Therapeutics figures

See a number that looks wrong?